LUNG CANCER How much platinum-based chemotherapy is enough in NSCLC?

被引：6

作者：

Peters, Solange ^{[1
]}

Adjei, Alex A. ^{[2
]}

机构：

[1] CHU Vaudois, Dept Oncol, CH-1011 Lausanne, Switzerland

[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 01期

关键词：

PHASE-III; RANDOMIZED TRIAL; METAANALYSIS; CISPLATIN; SURVIVAL; DURATION; COURSES; CYCLES;

D O I：

10.1038/nrclinonc.2014.212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4-6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.

引用

页码：8 / 9

页数：2

共 50 条

[41] HOW MUCH LUNG IS GOOD ENOUGH
WEIBEL, ER
EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1986, 69 : 37 - 45
[42] Banf1 Predicts Lung Cancer Survival and Sensitivity to Platinum-Based Chemotherapy
Plowman, J.
Bolderson, E.
Burgess, J.
Richard, D.
O'Byrne, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S832 - S832
[43] Efficacy and safety of non-platinum based doublets chemotherapy compared with platinum-based doublets chemotherapy in advanced non-small-cell lung cancer (NSCLC): a meta-analysis
Huang, Jing-Tao
Zhang, Zhong-Wei
Zhang, Yong-Min
Yan, Wen-Qiang
Li, Zhi-Gang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 15262 - 15273
[44] Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response
Fang, Chao
Li, Xiang-Ping
Chen, Yi-Xin
Wu, Na-Yiyuan
Yin, Ji-Ye
Zhang, Wei
Zhou, Hong-Hao
Liu, Zhao-Qian
JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3329 - 3340
[45] Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy
Moyer, Ann M.
Sun, Zhifu
Batzler, Anthony J.
Li, Liang
Schaid, Daniel J.
Yang, Ping
Weinshilboum, Richard M.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (03) : 811 - 821
[46] CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG-CANCER - HOW MUCH BENEFIT IS ENOUGH
GRILLI, R
OXMAN, AD
JULIAN, JA
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) : 1866 - 1872
[47] Platinum-Based Chemotherapy (CT) Rechallenge in Advanced Non Small Cell Lung Cancer (NSCLC) Patients (p): A Single Institution Experience
Carcereny, E.
Esteve, A. M.
Estival, A.
Domenech, M.
Angelats, L.
Erasun, C.
Gonzalez, A.
Plaja, A.
Garcia, N.
Espana, S.
Cucurull, M.
Ferrando, A.
Pous, A.
Notario, L.
Sanchez Martin, S.
Villacorta Garcia, C.
Moran, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S925 - S926
[48] Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Puskas, Rita
Bikov, Andras
Horvath, Peter
Lazar, Zsofia
Kunos, Laszlo
Nagy, Reka
Pinter, Gabriella
Galffy, Gabriella
PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
[49] Quality of life assessment of patients with metastatic lung cancer receiving platinum-based chemotherapy
Kivrak-Bernardelli, Beril G.
Macit, Caglar
Kadioglu, S. Beril
Salepci, Taflan
Clark, Philip M.
MARMARA PHARMACEUTICAL JOURNAL, 2013, 17 (02) : 120 - 130
[50] The Renaissance of Platinum-Based Chemotherapy for Metastatic Breast Cancer
Meriggi, F.
Di Biasi, B.
Zaniboni, A.
JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 551 - 560

← 1 2 3 4 5 →